Jubilant Pharmova allots ₹800 crore non-convertible debentures (NCDs)
Jubilant Pharmova (JUBLPHARMA) said it has allotted non-convertible debentures (NCDs) of ₹800 crore. The company is valued at about ₹14,953 crore.
What happened
In a filing with the BSE on 5 November 2026 at 10:22 PM, Jubilant Pharmova (JUBLPHARMA) said that it has allotted non-convertible debentures (NCDs) of ₹800 crore.
From the filing: "Thursday, November 5, 2026, have approved the allotment of 80,000 Unsecured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) of the face value of Rs. 1,00,000 per debenture, issued at par, aggregating to Rs. 800 crore on private placement basis to the successful bidders."
How big is it?
At ₹800 crore, the issue is equal to about 5.4% of the company's market value of ₹14,953 crore.
Company snapshot
Jubilant Pharmova is a small-cap company in the Healthcare sector, with a market value of about ₹14,953 crore.
The stock last traded at ₹938.8, against a 52-week range of ₹786.1–₹1,170 (19.8% below the high).
Before this filing the shares had moved −6.1% over the month and +0.6% over three months. Average daily turnover over the last 20 sessions was about ₹21.18 crore.
Promoters held 47.68% at the end of Q1 FY27; 6.58% of promoter shares were pledged. Foreign institutions owned 15.87% and domestic institutions 12.40%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,901 | 102.9 | 6.49 |
| Q2 FY26 | 1,966 | 120.3 | 7.59 |
| Q3 FY26 | 2,123 | 55.9 | 3.52 |
| Q4 FY26 | 2,290 | 119.4 | 7.55 |
| Q1 FY27 | 2,229 | 56.5 | 3.57 |
What history shows
BCEIE's records show 2 previous fund raising filings from the company since May 2026.
After those filings, the stock gained 1.1% on average the next trading day and was up 0.4% on average after five days (2 filings with price data).
Across 32 similar disclosures by other Healthcare companies, shares moved +0.8% on average the next day and +0.9% over five days; 53% of them rose the next day.
Market-wide, 1,733 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 12 Oct 2026 | Issue of Secured / Unsecured, Listed, Rated, Redeemable… | +1.1% | +0.4% |
| 12 Oct 2026 | Issuance of Secured / Unsecured, Listed, Rated, Redeemable… | +1.1% | +0.4% |
What to watch
- How the money raised is used and, for equity instruments, the dilution for existing shareholders.
- 13 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say
- India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
- Jubilant Pharmova Q2FY27 Results: Earnings webinar scheduled for Nov 16
- Jubilant Pharmova Lines Up A 14 Billion-Rupee Bond Sale
- CDMO Jubilant Pharmova to raise $150-M via bonds
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.